Search hospitals > Kansas > Mission

University of Kansas Clinical Research Center

Claim this profile
Mission, Kansas 66205
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Lymphoma
Conducts research for Leukemia
Conducts research for Adenocarcinoma
152 reported clinical trials
45 medical researchers
Photo of University of Kansas Clinical Research Center in MissionPhoto of University of Kansas Clinical Research Center in MissionPhoto of University of Kansas Clinical Research Center in Mission

Summary

University of Kansas Clinical Research Center is a medical facility located in Mission, Kansas. This center is recognized for care of Cancer, Tumors, Lymphoma, Leukemia, Adenocarcinoma and other specialties. University of Kansas Clinical Research Center is involved with conducting 152 clinical trials across 544 conditions. There are 45 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Jeffrey Statland.

Area of expertise

1Cancer
Global Leader
University of Kansas Clinical Research Center has run 49 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
PD-L1 positive
2Tumors
Global Leader
University of Kansas Clinical Research Center has run 31 trials for Tumors. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive

Top PIs

Clinical Trials running at University of Kansas Clinical Research Center

Acute Myeloid Leukemia
Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Pancreatic Cancer
Prostate Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Non-Hodgkin's Lymphoma
Renal Cell Carcinoma
Image of trial facility.

CYAD-02

for Leukemia/Preleukemia

This study is evaluating whether a drug may help treat patients with acute myeloid leukemia or myelodysplastic syndrome.
Recruiting3 awards Phase 16 criteria
Image of trial facility.

Targeted Therapies

for Acute Myeloid Leukemia

This study is evaluating whether genomic screening followed by assignment to a multi-study protocol may help identify new treatments for leukemia.
Recruiting1 award Phase 1 & 24 criteria
Image of trial facility.

GLB-001

for Acute Myeloid Leukemia

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximately 24 participants (up to 42 participants) may be enrolled in Phase 1a of the study. The dose expansion part (Phase 1b) will be followed to understand the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Up to 24 participants (12 participants per dose level) may be enrolled in Phase 1b of the study.
Recruiting1 award Phase 16 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Kansas Clinical Research Center?
University of Kansas Clinical Research Center is a medical facility located in Mission, Kansas. This center is recognized for care of Cancer, Tumors, Lymphoma, Leukemia, Adenocarcinoma and other specialties. University of Kansas Clinical Research Center is involved with conducting 152 clinical trials across 544 conditions. There are 45 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Jeffrey Statland.